Hangzhou Diagens Biotechnology Co (HKSE:02526) LT-Debt-to-Total-Asset: 0.01 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02526 Hangzhou Diagens Biotechnology Co Ltd HKSE:02526
8 GF Score
Price HK$370.00
! 1 Warning Sign
View Full Analysis

What is Hangzhou Diagens Biotechnology Co LT-Debt-to-Total-Asset?

Hangzhou Diagens Biotechnology Co HKSE:02526 -1.07% 8 LT-Debt-to-Total-Asset is 0.01 as of Jun. 2026. GuruFocus rates HKSE:02526 with a GF Score™ of 8/100. The stock has 1 warning sign investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Hangzhou Diagens Biotechnology Co's long-term debt to total assests ratio for the quarter that ended in Jun. 2026 was 0.01.

Hangzhou Diagens Biotechnology Co's long-term debt to total assets ratio stayed the same from Dec. 2023 (0.01) to Jun. 2026 (0.01).

Hangzhou Diagens Biotechnology Co  (HKSE:02526) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Hangzhou Diagens Biotechnology Co LT-Debt-to-Total-Asset Related Terms

Hangzhou Diagens Biotechnology Co LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Hangzhou Diagens Biotechnology Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hangzhou Diagens Biotechnology Co LT-Debt-to-Total-Asset Chart

Hangzhou Diagens Biotechnology Co Annual Data
Trend Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
0.01 0.03 0.02

Hangzhou Diagens Biotechnology Co Quarterly Data
Dec23 Dec24 Sep25 Dec25 Jun26
LT-Debt-to-Total-Asset 0.01 0.03 0.02 0.02 0.01
HKSE:02526
8GF Score
Hangzhou Diagens Biotechnology Co Ltd HKSE:02526
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hangzhou Diagens Biotechnology Co LT-Debt-to-Total-Asset Calculation

Hangzhou Diagens Biotechnology Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=4.913/238.154
=0.02

Hangzhou Diagens Biotechnology Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2026 is calculated as

LT Debt to Total Assets (Q: Jun. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Jun. 2026 )/Total Assets (Q: Jun. 2026 )
=4.969/1029.906
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.01 mean?
Hangzhou Diagens Biotechnology Co (HKSE:02526) has a LT-Debt-to-Total-Asset of 0.01 as of Jun. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Hangzhou Diagens Biotechnology Co and its competitors.
Is Hangzhou Diagens Biotechnology Co's LT-Debt-to-Total-Asset too high?
Hangzhou Diagens Biotechnology Co's current LT-Debt-to-Total-Asset is 0.01. Overall, Hangzhou Diagens Biotechnology Co has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Hangzhou Diagens Biotechnology Co's LT-Debt-to-Total-Asset compare to ABT and SYK?
Hangzhou Diagens Biotechnology Co's LT-Debt-to-Total-Asset of 0.01 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?
A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Hangzhou Diagens Biotechnology Co and its competitors. Hangzhou Diagens Biotechnology Co's current LT-Debt-to-Total-Asset is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou Diagens Biotechnology Co stock overvalued right now?
Hangzhou Diagens Biotechnology Co (HKSE:02526) has a current LT-Debt-to-Total-Asset of 0.01. The current LT-Debt-to-Total-Asset is 0.01. Hangzhou Diagens Biotechnology Co's overall GF Score™ is 8/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Hangzhou Diagens Biotechnology Co (HKSE:02526), the current LT-Debt-to-Total-Asset is 0.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hangzhou Diagens Biotechnology Co Business Description

Address No. 609 Hongfeng Road, Room 101, Building 1, Donghu Sub-district, Linping District, Zhejiang, Hangzhou, CHN
Hangzhou Diagens Biotechnology Co Ltd and its subsidiaries are involved in the development and commercialisation of medical imaging artificial intelligence technologies and medical imaging equipment. It has self-developed a diversified portfolio, including six medical imaging software products, three commercialized medical devices, four key reagents and consumables and two technology licensing offerings. Its Core Product, AI AutoVision, is an auxiliary diagnostic software designed to undertake intelligent analysis on chromosome karyotyping. The majority of the company's revenue is derived from Technology Licensing, mainly in the Chinese mainland.
8GF Score

Get the complete analysis for HKSE:02526

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$370.00
Price